Sterling Biotech Sustainability Profile
Sterling Biotech, headquartered in India, is a prominent player in the pharmaceutical and biotechnology industry, specialising in the production of high-quality pharmaceutical excipients and active pharmaceutical ingredients (APIs). Founded in 1995, the company has established a strong presence in both domestic and international markets, with significant operations across Asia, Europe, and the Americas. Renowned for its innovative approach, Sterling Biotech offers a diverse range of products, including starches, cellulose derivatives, and other excipients that enhance drug formulation. The company’s commitment to quality and sustainability has positioned it as a trusted partner for pharmaceutical manufacturers worldwide. With a focus on research and development, Sterling Biotech continues to achieve notable milestones, reinforcing its reputation as a leader in the biopharmaceutical sector.
DitchCarbon Score
How does Sterling Biotech's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Sterling Biotech's score of 38 is higher than 63% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Sterling Biotech, headquartered in India, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Zydus Lifesciences Limited, which influences its climate commitments and emissions reporting. As part of its corporate family, Sterling Biotech inherits climate initiatives and targets from Zydus Lifesciences Limited. However, there are no documented reduction targets or significant climate pledges reported for Sterling Biotech at this time. The absence of specific emissions data and reduction initiatives suggests that the company may still be in the early stages of formalising its climate strategy. In the context of the industry, it is essential for companies like Sterling Biotech to establish clear carbon reduction targets and transparent reporting practices to align with global climate goals. As the landscape of corporate sustainability evolves, the pressure to disclose emissions data and commit to science-based targets will likely increase.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Scope 1 | 92,070,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 168,794,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | 0,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
How Carbon Intensive is Sterling Biotech's Industry?
How Carbon Intensive is Sterling Biotech's Location?
Sterling Biotech's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Sterling Biotech has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
